Recursion Pharmaceuticals (RXRX) is back in focus after recent clinical updates on its AI-driven pipeline and in advance of its presentation at the Goldman Sachs Global Healthcare Conference in Miami on June 9, 2026.

Despite the recent 4.44% 1 day share price gain to US$3.29 and a 12.29% 1 month share price return that reflects fresh interest around Recursion Pharmaceuticals' AI platform and trial updates, longer term total shareholder returns over 1, 3 and 5 years remain sharply lower. This indicates that sentiment has yet to recover in a sustained way.

If Recursion's AI driven drug discovery story has your attention, it can be useful to compare it with other opportunities in the space by scanning 39 healthcare AI stocks.

So with Recursion Pharmaceuticals stock still well below its multi year highs, yet attracting fresh interest around its AI driven pipeline and upcoming catalysts, are you looking at an overlooked opportunity here or a market already pricing in future growth?

Most Popular Narrative: 67% Overvalued

Based on the most followed narrative, Recursion Pharmaceuticals stock at $3.29 is being compared with a fair value estimate of $1.97, which points to a large gap between the narrative view and the current market price.

Recursion Pharmaceuticals (RXRX) one day will be the Palantir of biotechnology! With the CMO transitioning out as well as the former CEO, RXRX now has a chance to take off! Vikki Goodman and Najat Khan can now lead RXRX back to respectability and acceptance as a real leader in biotechnology! Once the announcements start coming in on REC-4881 going to Phase 3 and beyond this stock will skyrocket! RXRX finally has the right people in place to do their jobs correctly! Many institutions will soon be coming in with more good news to follow!!!

Want to see what sits behind that optimism on Recursion Pharmaceuticals? The narrative leans heavily on aggressive revenue expansion, margin improvement and a future earnings multiple that assumes sustained progress across the pipeline. Curious how those moving parts combine into a single fair value number and how sensitive it is to even small changes in growth or profitability assumptions? The full narrative lays out those building blocks in detail so you can judge the story for yourself.

Result: Fair Value of $1.97 (OVERVALUED)

However, Recursion Pharmaceuticals still faces clear risks, including ongoing net losses of $559.776 million and multi year shareholder returns that remain sharply lower from past levels.

Another View on Recursion Pharmaceuticals Using the SWS DCF Model

The narrative based fair value of $1.97 suggested Recursion Pharmaceuticals stock looked stretched at $3.29. Our DCF model, however, points to a future cash flow value of $9.09, which implies upside rather than downside. When two methods disagree this much, which set of assumptions do you trust more?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Recursion Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment clearly split between upside potential and past losses, move quickly to review the full picture of risks and rewards so you can build your own view using 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Recursion Pharmaceuticals?

If Recursion Pharmaceuticals has sharpened your focus on stock selection, do not stop here, the next opportunity you research could be the one that reshapes your portfolio.

• Spot potential turnaround stories early by scanning 23 elite penny stocks with strong financials before attention truly shifts and prices move ahead of you.
• Zero in on quality at a discount with 47 high quality undervalued stocks so you are not left watching others act on opportunities you never reviewed.
• Prioritize resilience and sleep better at night by checking stocks in the 68 resilient stocks with low risk scores that aim to balance return potential with steadier risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.